P

    Palvella Therapeutics, Inc (PVLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $152.59
    +2.62 (+1.75%)

    Market Cap: $2.16B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    9%(3/34)
    Avg Surprise
    -4071.78%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.74
    Range$-2.31 - $-1.05
    12 analysts
    EPS Revisions
    1
    0
    7d
    1
    6
    30d
    EPS Estimate Drift
    90d ago$-1.40+19.4%
    60d ago$-1.47+15.5%
    30d ago$-1.47+15.6%
    7d ago$-1.47+15.6%
    Current$-1.74
    Revenue Consensus
    $0
    Range$0 - $0
    14 analysts
    Dec 31, 2026
    EPS Consensus$-2.56
    Range$-4.03 - $-0.14
    13 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.56---
    Sep 26EST
    		-$-1.74---
    Jun 26
    		$-1.52$-1.16-31.03%Miss-76.7%
    Mar 26
    		$-1.20$-0.93-29.03%Miss-62.2%
    Dec 25
    		$-1.08$-0.91-18.58%Miss+79.9%
    Sep 25
    		$-1.03$-0.85-21.18%Miss+52.9%
    Jun 25
    		$-0.86$-0.77-11.69%Miss+68.9%
    Mar 25
    		$-0.74N/A+78.24%Beat+81.3%
    Dec 24
    		$-5.37$-0.60-798.74%Miss-44.9%
    Sep 24
    		$-2.19N/AN/ABeat+74.9%
    Jun 24
    		$-2.76$-0.03-9112.33%Miss-169.1%
    Mar 24
    		$-3.95$-0.06-6491.17%Miss+72.5%
    Dec 23
    		$-3.71$-0.12-2988.92%Miss+57.9%
    Sep 23
    		$-8.70$-0.11-7810.45%Miss+16.3%
    Jun 23
    		$4.00$-0.16+2652.65%Beat+135.7%
    Mar 23
    		$-14.40$-0.18-7747.41%Miss-157.1%
    Dec 22
    		$-8.80$-0.23-3726.09%Miss+26.7%
    Sep 22
    		$-10.40$-0.16-6400.00%Miss+45.8%
    Jun 22
    		$-11.20$-0.11-10081.82%Miss+44.0%
    Mar 22
    		$-5.60$-0.12-4769.57%Miss+0.0%
    Dec 21
    		$-12.00$-0.14-8788.89%Miss+42.3%
    Sep 21
    		$-19.20$-0.24-7791.49%Miss+7.7%
    Jun 21
    		$-20.00$-0.22-8990.91%Miss-177.8%
    Mar 21
    		$-5.60$-0.17-3194.12%Miss+0.0%
    Dec 20
    		$-20.80$-0.23-8846.24%Miss-333.3%
    Sep 20
    		$-20.80$-0.13-15900.00%Miss-420.0%
    Jun 20
    		$-7.20$-0.17-4135.29%Miss+62.5%
    Mar 20
    		$-5.60$-0.17-3194.12%Miss+65.0%
    Dec 19
    		$-4.80$-0.28-1614.29%Miss+72.7%
    Sep 19
    		$-4.00$-0.17-2252.94%Miss+54.5%
    Jun 19
    		$-19.20$-0.22-8627.27%Miss-6283.0%
    Mar 19
    		$-16.00$-0.20-7900.00%Miss-9311.8%
    Dec 18
    		$-17.60$-0.18-9677.78%Miss-222.2%
    Sep 18
    		$-8.80$-0.12-7233.33%Miss+30.8%
    Jun 18
    		$-0.30$-0.01-2908.00%Miss+98.4%
    Mar 18
    		$-0.17$-0.02-750.00%Miss+98.9%
    Dec 17
    		$14.40$-0.07+20671.43%Beat+218.2%
    Sep 17
    		$-12.72N/AN/ABeat-10.5%
    Jun 17
    		$-18.59N/AN/ABeat-
    Mar 17
    		$-14.85N/AN/ABeat-
    Dec 16
    		$-12.19N/AN/ABeat-
    Sep 16
    		$-11.51N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-31.59EV/EBITDAN/A
    Price/FCF-60.00xFCF Yield-1.67%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-46.60%ROIC-11.40%
    Financial Health
    Debt/Equity0.00xInterest Coverage-4.12x
    Current Ratio21.18xQuick Ratio21.18x
    Trading Statistics
    BetaN/AAvg Volume190.16K
    52-Week High$161.3852-Week Low$50.82

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$148.62
    SMA 20$151.68
    SMA 50$146.13
    SMA 200$117.43
    EMA 10$150.19
    EMA 20$149.45
    EMA 50$143.72
    EMA 200$116.36

    MACD

    Line: 1.55Signal: 1.98Hist: -0.43

    ADX

    ADX: 14.1+DI: 14.9-DI: 20.9

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down24.0
    PSAR$137.97

    Bollinger Bands

    Upper Band$160.43
    Lower Band$142.93
    %B Position1154%(Upper)
    Band Width0.55

    RSI (14-Day)

    Neutral
    54.5

    Momentum Oscillators

    Stoch %K61.4
    Stoch %D62.2
    Williams %R-31.9
    ROC (10d)-0.6%
    Momentum-0.93
    CCI (20d)-32.0
    MFI (14d)43.0

    Volatility Measures

    ATR (14d)$8.61(5.6%)
    StdDev (20d)4.37
    Hist Vol44.6%(High)

    Volume Flow

    VWAP$149.65
    OBV10.0M
    AD Line6.8M
    CMF (20d)0.042

    Volume Metrics

    Avg Vol (20d)192.4K
    Vol Ratio1.3x
    VWMA (20d)$151.34

    Pivot Points

    R3$157.65
    R2$155.46
    R1$152.72
    Pivot Point$150.53
    S1$147.79
    S2$145.60
    S3$142.86

    Advanced Oscillators

    TSI5.42
    Ultimate Osc61.4
    KST22.49

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$53,000$1.30M$19.52M
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/A$-30,000N/A$739,000
    Gross ProfitN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$1.30M$18.78M
    Operating Expenses$21.41M$14.86M$11.30M$10.18M$9.25M$7.87M$4.37M$5.06M$2.91M$1.76M$6.78M$15.70M
    R&D$12.47M$9.33M$7.12M$6.53M$5.12M$4.07M$2.54M$3.20M$1.44M$984,000$4.45M$9.60M
    SG&A$8.93M$5.52M$4.18M$3.65M$4.13M$3.80M$1.82M$1.88M$1.47M$775,000$0$0
    Operating Income$-21,405,000$-14,855,000$-11,304,000$-10,177,000$-9,250,000$-7,871,000$-4,366,000$-5,062,000$-2,908,000$-1,759,000$-5,482,000$3.09M
    Interest Income$1.97M$1.07M$520,000$628,000$690,000$752,000$0$187,000$0$86,000$0$0
    Interest Expense$2.31M$2.04M$1.74M$1.51M$1.35M$1.22M$1.30M$1.24M$1.06M$805,000$0$13.84M
    Income Before Tax$-21,870,000$-15,767,000$-12,714,000$-11,345,000$-9,471,000$-8,185,000$-3,951,000$-6,775,000$-4,172,000$-2,536,000$-4,584,000$-10,752,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-21,870,000$-15,767,000$-12,714,000$-11,345,000$-9,471,000$-8,185,000$-3,951,000$-6,775,000$-4,172,000$-2,536,000$-4,584,000$-10,752,000
    EBITDA$-21,562,000$-17,806,000$-10,975,000$342,000$-8,117,000$-6,970,000$-2,647,000$-1,713,000$-3,115,000$-1,731,000$-4,584,000$-10,013,000
    EBITN/AN/AN/A$-9,835,000$-9,250,000$-7,871,000N/A$-6,775,000$-4,176,999$-1,701,000$-5,482,000$-10,752,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PVLA

    News

    36,259 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Blue Owl Capital Holdings LP

    Blue Owl Capital Holdings LP has acquired 36,259 shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the second quarter, making it the 21st biggest holding in their portfolio. Other institutional investors like The Manufacturers Life Insurance Company and Jennison Associates LLC also significantly increased their stakes. The article notes that analysts have a consensus "Buy" rating for Palvella Therapeutics with an average target price of $209.14, and includes recent insider selling activity from the COO.

    MarketBeat•8/21/26•
    Somewhat-Bullish

    Palvella Therapeutics COO Kathleen Goin Executes Stock Option Exercises and Sells Shares Under Rule 10b5-1 Plan

    Kathleen Goin, COO of Palvella Therapeutics, exercised stock options and sold 4,302 common shares on August 19, 2026, under a pre-established Rule 10b5-1 trading plan. The transactions resulted in her direct beneficial ownership of common stock becoming zero, although she retains additional stock options. The company noted that such trading plans are used by officers for various personal reasons, including tax requirements and investment diversification.

    Kalkine Media•8/21/26•
    Neutral

    Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells $654,807.42 in Stock

    Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of company stock for $654,807.42 on August 19th, reducing her direct ownership by 66.64%. This sale follows another transaction in June and occurred as PVLA shares declined by 4.9% and the company missed analyst earnings estimates. Despite the insider selling and earnings miss, analysts maintain a consensus "Buy" rating for PVLA.

    MarketBeat•8/20/26•
    Somewhat-Bearish

    Palvella Therapeutics (NASDAQ: PVLA) COO sells 4,302 shares under 10b5-1 plan

    Palvella Therapeutics (NASDAQ: PVLA) Chief Operating Officer Kathleen Goin sold 4,302 shares of common stock at prices ranging from $150.62 to $156.77 per share. These sales were executed on August 19, 2026, under a pre-established Rule 10b5-1 trading plan adopted on August 19, 2025, following the exercise of fully vested stock options. The transactions generated approximately $655,000 in gross sale proceeds from an approximate exercise cost of $35,000.

    Stock Titan•8/20/26•
    Neutral

    Lisanti Capital Growth LLC Purchases Shares of 42,975 Palvella Therapeutics, Inc. $PVLA

    Lisanti Capital Growth LLC recently acquired 42,975 shares of Palvella Therapeutics (NASDAQ:PVLA), a new position valued at approximately $6.57 million, representing 1.4% of its portfolio. This acquisition gives the fund about 0.30% ownership in Palvella, where institutional investors collectively hold 40.11% of the stock. Despite a recent earnings miss and a sale by COO Kathleen Goin, analyst sentiment remains largely positive with an average "Buy" rating and a target price of $209.14.

    MarketBeat•8/20/26•
    Neutral

    Frequently Asked Questions About PVLA

    Does PVLA pay dividends?
    Palvella Therapeutics, Inc (PVLA) does not currently pay a regular dividend.
    What is PVLA's market cap?
    Palvella Therapeutics, Inc (PVLA) has a market capitalization of $2.16B with a current stock price of $152.59.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In